AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
SAN DIEGO, April 22, 2026 /PRNewswire/ — Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and…
